FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964205145> ?p ?o ?g. }

• W2964205145 endingPage "4452" @default.
• W2964205145 startingPage "4452" @default.
• W2964205145 abstract "Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism mediated by natural killer (NK) cells that has been shown to significantly contribute to the anti-tumor effect of therapeutic monoclonal antibodies (mAbs) including rituximab (anti-CD20), cetuximab (anti-EGFR) and trastuzumab (anti-ErbB2). ADCC is induced by the crosslinking of the FcγRIIIA (CD16a) receptor expressed on NK cells with cell surface-bound IgG antibodies. Upon NK cell activation, CD16a is proteolytically cleaved from the surface of NK cells, a process that decreases ADCC. There exist two allelic variants of CD16a, with the high-affinity CD16a 158V allele found in about 10% of the population. Additionally, we previously identified a single substitution mutation that renders CD16a resistant to activation-induced cleavage. Engineering of human induced pluripotent stem cells (hiPSCs) with a non-cleavable version of the high-affinity CD16a 158V variant, followed by differentiation of hiPSCs to NK cells, enables us to develop an off-the-shelf NK cell therapy with improved ADCC properties when combined with monoclonal antibody therapy for treatment of both hematologic malignancies and solid tumors. We evaluated cell surface phenotype, as well as the in vitro and in vivo tumor-killing function, of these high affinity, non-cleavable CD16a iNK (hnCD16-iNK) cells alone and in combination with anti-CD20 mAb against multiple B-cell leukemia and lymphoma targets. In contrast to the endogenous expression of CD16a on peripheral blood NK (PB-NK) cells, which is variable depending on the donor, the derivation of NK cells from a clonal hiPSC line engineered to express hnCD16a produced a uniform population of CD16+ NK cells (>95% CD16+ for hnCD16-iNK vs. 40-60% CD16+ PB-NK cells). These hnCD16-iNK cells are phenotypically mature, highly functional in vitro, and exhibit enhanced ADCC when combined with anti-CD20 mAb against multiple lymphoma targets, including Raji, Nalm6 and Jeko-1. Both direct and CD16-mediated activation of hnCD16-iNK cells result in production of the inflammatory cytokines tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ). Furthermore, in contrast to PB-NK cells, hnCD16-iNK cells proved to be highly resistant to activation-induced cleavage of CD16 in response to Raji cells coated with anti-CD20 (68±26% cleavage for PB-NK vs. 8.0±4.2% cleavage for hnCD16-iNK cells). To extend these findings to an in vivo model, we treated Raji-lymphoma bearing mice with either anti-CD20 mAb (rituximab) alone or in combination with either PB-NK cells or hnCD16-iNK cells. Combination treatment with hnCD16-iNK cells enhanced the efficacy of anti-CD20 compared to mAb treatment only, and provided improved tumor regression compared to mAb plus PB-NK (p 50 days for combination treatment with hnCD16-iNK). Similar results were seen with the combination of anti-HER2 antibody and hnCD16-iNK cells in an SKOV3 ovarian cancer mouse model. In summary, these data demonstrate that combination therapy hnCD16-iNK cells with monoclonal antibody therapy is highly functional against various tumor cell lines in vitro and in vivo, and justify further investigation into their clinical application to enhance ADCC and the anti-tumor effects of therapeutic mAbs. Disclosures Bjordahl: Fate Therapeutics: Employment, Equity Ownership. Gaidarova: Fate Therapeutics Inc.: Employment, Equity Ownership. Rogers: Fate Therapeutics Inc.: Employment, Equity Ownership. Kaufman: Fate Therapeutics: Consultancy, Research Funding. Valamehr: Fate Therapeutics: Employment, Equity Ownership." @default.
• W2964205145 created "2019-07-30" @default.
• W2964205145 creator A5002793798 @default.
• W2964205145 creator A5011430525 @default.
• W2964205145 creator A5014180019 @default.
• W2964205145 creator A5022682897 @default.
• W2964205145 creator A5027299607 @default.
• W2964205145 creator A5054016372 @default.
• W2964205145 creator A5064341938 @default.
• W2964205145 creator A5070964738 @default.
• W2964205145 date "2017-12-07" @default.
• W2964205145 modified "2023-09-29" @default.
• W2964205145 title "Genetically Engineered Pluripotent Cell-Derived Natural Killer Cell Therapy Provides Enhanced Antibody Dependent Cellular Cytotoxicity Against Hematologic Malignancies and Solid Tumors in Combination with Monoclonal Antibody Therapy" @default.
• W2964205145 doi "https://doi.org/10.1182/blood.v130.suppl_1.4452.4452" @default.
• W2964205145 hasPublicationYear "2017" @default.
• W2964205145 type Work @default.
• W2964205145 sameAs 2964205145 @default.
• W2964205145 citedByCount "0" @default.
• W2964205145 crossrefType "journal-article" @default.
• W2964205145 hasAuthorship W2964205145A5002793798 @default.
• W2964205145 hasAuthorship W2964205145A5011430525 @default.
• W2964205145 hasAuthorship W2964205145A5014180019 @default.
• W2964205145 hasAuthorship W2964205145A5022682897 @default.
• W2964205145 hasAuthorship W2964205145A5027299607 @default.
• W2964205145 hasAuthorship W2964205145A5054016372 @default.
• W2964205145 hasAuthorship W2964205145A5064341938 @default.
• W2964205145 hasAuthorship W2964205145A5070964738 @default.
• W2964205145 hasConcept C153911025 @default.
• W2964205145 hasConcept C159654299 @default.
• W2964205145 hasConcept C203014093 @default.
• W2964205145 hasConcept C40677261 @default.
• W2964205145 hasConcept C502942594 @default.
• W2964205145 hasConcept C542903549 @default.
• W2964205145 hasConcept C86803240 @default.
• W2964205145 hasConceptScore W2964205145C153911025 @default.
• W2964205145 hasConceptScore W2964205145C159654299 @default.
• W2964205145 hasConceptScore W2964205145C203014093 @default.
• W2964205145 hasConceptScore W2964205145C40677261 @default.
• W2964205145 hasConceptScore W2964205145C502942594 @default.
• W2964205145 hasConceptScore W2964205145C542903549 @default.
• W2964205145 hasConceptScore W2964205145C86803240 @default.
• W2964205145 hasLocation W29642051451 @default.
• W2964205145 hasOpenAccess W2964205145 @default.
• W2964205145 hasPrimaryLocation W29642051451 @default.
• W2964205145 hasRelatedWork W1967455230 @default.
• W2964205145 hasRelatedWork W2005942119 @default.
• W2964205145 hasRelatedWork W2113170011 @default.
• W2964205145 hasRelatedWork W2553129782 @default.
• W2964205145 hasRelatedWork W2557984292 @default.
• W2964205145 hasRelatedWork W2808995183 @default.
• W2964205145 hasRelatedWork W2898703961 @default.
• W2964205145 hasRelatedWork W2903132419 @default.
• W2964205145 hasRelatedWork W2906967180 @default.
• W2964205145 hasRelatedWork W2914392824 @default.
• W2964205145 hasRelatedWork W2924639874 @default.
• W2964205145 hasRelatedWork W2949152803 @default.
• W2964205145 hasRelatedWork W2973118810 @default.
• W2964205145 hasRelatedWork W2979293535 @default.
• W2964205145 hasRelatedWork W2995447672 @default.
• W2964205145 hasRelatedWork W3000621340 @default.
• W2964205145 hasRelatedWork W3046482508 @default.
• W2964205145 hasRelatedWork W3087276994 @default.
• W2964205145 hasRelatedWork W3099802169 @default.
• W2964205145 hasRelatedWork W3209464193 @default.
• W2964205145 hasVolume "130" @default.
• W2964205145 isParatext "false" @default.
• W2964205145 isRetracted "false" @default.
• W2964205145 magId "2964205145" @default.
• W2964205145 workType "article" @default.